Glatt to inaugurate vaccine production in Ghana with fill and finish plant

Glatt in Weimar, Germany has been commissioned to conduct a concept study to investigate the technical and economic aspects of a fill and finish plant for vaccines. The independent, fully integrated state-of-the-art biotechnological facility is to be built in Accra, Ghana.

The current pandemic has underscored the need for vaccine production in Africa. Through government’s vaccine development and manufacturing presidential committee (VMC), Ghanaian President Nana Addo Dankwa Akufo-Addo has convened a board to establish a 10-year plan for vaccine development and production. The most promising near-term approach to achieve this goal is the construction of a bottling and packaging plant, which will lay the foundation in the region for vaccine production against COVID-19 and other diseases.

An artist's impression of the planned vaccine production facility to be based in Accra, Ghana
An artist’s impression of the planned biotechnological vaccine production facility to be based in Accra, Ghana (source: Glatt)

As a process expert and working in close collaboration with the vaccine manufacturer, Glatt will provide detailed planning services for the plant, investigate its technical feasibility and provide economic efficiency advice.

The current planning envisages the filling of vaccines in four independent production modules. Single-use components for different primary packaging materials will be used.

A closer look at the planned facility

The plant will be operated by DEK Vaccines, a company founded by three pharmaceutical manufacturers based in Africa. The project comprises three phases, which will be implemented on a step-by-step basis. The specific requirements for the manufacture of current and future products are already being incorporated into Glatt’s planning to ensure a smooth production process. The same approach is being applied to legal conditions and standards.

Deutsche Gesellschaft für Internationale Zusammenarbeit (GIZ) has commissioned Glatt for phase 1 of the project. 

The main building and administration wing will occupy 7 000m2, encompassing various essential areas on different floors. These include the warehouse and logistics level, a mezzanine for changing rooms with an adjacent canteen and a floor for administration and technology. The heart of the facility, the production level, will comprise two preparation and formulation units for different vaccine categories (up to biosafety level 1), a R&D area and quality control laboratory.

After the successful completion of all phases, the plant will be able to fill at least 100m vaccine doses per shift, per year. The facility will serve as a blueprint to establish vaccine production in west Africa.

In South Africa, Glatt is represented by Reitech SA.

Visit the official COVID-19 government website to stay informed: sacoronavirus.co.za